Allergan Gains Sanctura XR Rights With Esprit Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus is in “a far stronger marketing position” for the overactive bladder product under a new license agreement with Allergan, Indevus CEO says.
You may also be interested in...
Indevus Rides High On Double Good News
No new trials for testosterone therapy, FDA says; separate Teva deal sweetens the pot.
Indevus Rides High On Double Good News
No new trials for testosterone therapy, FDA says; separate Teva deal sweetens the pot.
Indevus Gains Sanctura XR Approval
The molecule’s “highly differentiated profile” will set it apart from others in the crowded urinary incontinence space, Indevus tells “The Pink Sheet” DAILY.